As AI finds solid footing in pharma R&D, the technology is slated to yield significant rewards.
Industry leaders expect that up to 30% of preclinical work could soon be accomplished using some form of AI, according to a recent survey, and ultimately predict a 16% reduction in drug development costs with the use of AI in general.
